JPRN-UMIN000011559
Completed
未知
Therpeutic drug monitoring of Everolimus in patients with renal cell carcinoma and tuberous sclerosis - TDM study of Everolimus
Department of Urology, Keio University School of Medicine0 sites43 target enrollmentSeptember 1, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Urology, Keio University School of Medicine
- Enrollment
- 43
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Pregnancy Interstitial lung marking in chest imaging Infection Liver dysfunction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
Completed
Phase 4
Maintenance therapy with Everolimus in patients with tuberous sclerosis successfully treated for subependymal giant cell astrocytomaQ85.1D33.0Tuberous sclerosisBrain, supratentorialDRKS00005584Medical University of Lodz12
Not yet recruiting
Not Applicable
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Everolimus tablet with brand drugs (AFINITOR® 10mg Novartis).IRCT20200105046010N44SOBHAN ONCOLOGY Pharmaceutical CO.24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).IRCT20200105046010N58anoalvand Pharmaceutical Co.24